Add to Twitter
 
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
• Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer patients

• Blackstone Life Sciences will invest $400 million USD and their expertise to accelerate the future development and commercialization of nadofaragene firadenovec, an investigational gene therapy

• The FDA has accepted the Biologics License Application (BLA) for filing and granted Priority Review for nadofaragene firadenovec

• Phase 3 results to be presented at Society of Urologic Oncology 20th Annual Meeting in Washington DC on December 5, 2019